Then and now: Studies using a burned mouse model reflect trends in burn research over the past 25 years

Burns

Volumn 25, Issue 7, 1999, Pages 603-609

  Neely, Alice N ^a   Holder, Ian Alan ^a   Warden, Glenn D ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CYTOKINE; ENDOTOXIN; PSEUDOMONAS VACCINE; VIRULENCE FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; BACTERIAL FLORA; BACTERIAL VIRULENCE; BURN; MOUSE; NONHUMAN; PATHOGENESIS; PSEUDOMONAS AERUGINOSA; REVIEW; SEPSIS; SKIN INFECTION;

EID: 0033231784     PISSN: 03054179     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-4179(99)00068-6     Document Type: Short Survey

References (93)

1. Stieritz D.D., Holder I.A. Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: description of a burned mouse model. J. Infect. Dis. 131:1975;688-691.
2. Cryz S.J. Jr., Cross A.S., Furer E., Chariatte N., Sadoff J.C., Germanier R. Activity of intravenous immune globulins against Klebsiella. J. Lab. Clin. Med. 108:1986;182-189.
3. Cryz S.J. Jr., Furer E., Germanier R. Protection against Pseudomonas aeruginosa infection in a murine burn wound sepsis model by passive transfer of antitoxin A, antielastase and antilipopolysaccharide. Infect. Immun. 39:1983;1072-1079.
4. Cryz S.J. Jr., Furer F., Germanier R. Experimental Klebsiella pneumoniae burn wound sepsis: role of capsular polysaccharide. Infect. Immun. 43:1984;440-441.
5. Cryz S.J. Jr., Furer E., Germanier R. Prevention of fatal experimental burn-wound sepsis due to Klebsiella pneumoniae KP1-O by immunization with homologous capsular polysaccharide. J. Infect. Dis. 150:1984;817-822.
6. Cryz S.J. Jr., Furer E., Germanier R. Protection against fatal Pseudomonas aeruginosa burn wound sepsis by immunization with lipopolysaccharide and high-molecular weight polysaccharide. Infect. Immun. 43:1984;795-799.
7. Cryz S.J. Jr., Furer E., Germanier R. Protection against fatal Klebsiella pneumoniae burn wound sepsis by passive transfer of anticapsular polysaccharide. Infect. Immun. 45:1984;139-142.
8. Cryz S.J. Jr., Furer E., Sadoff J.C., Fredeking T., Que J.U., Cross A.S. Production and characterization of a human hyperimmune intravenous immunoglobulin against Pseudomonas aeruginosa and Klebsiella species. J. Infect. Dis. 163:1991;1055-1061.
9. Cryz S.J. Jr., Furer E., Sadoff J.C., Germanier R. Pseudomonas aeruginosa immunotype 5 polysaccharide-toxin A conjugate vaccine. Infect. Immun. 52:1986;161-165.
10. Cryz S.J. Jr., Lang A.B., Sadoff J.C., Germanier R., Furer E. Vaccine potential of Pseudomonas aeruginosa O-polysaccharide-toxin A conjugates. Infect. Immun. 55:1987;1547-1551.
11. Ochi H., Ohtsuka H., Yokota S.-I., et al. Inhibitory activity on bacterial motility and in vivo protective activity of human monoclonal antibodies against flagella of Pseudomonas aeruginosa. Infect. Immun. 59:1991;550-554.
12. Okada K., Kawaharajo K., Kasai T., Homma J.Y. Effects of somatic component of Pseudomonas aeruginosa on protective immunity in experimental mouse burn infection. Jpn. J. Exp. Med. 50:1980;53-61.
13. Sato H., Okinaga K. Role of pili in the adherence of Pseudomonas aeruginosa to mouse epidermal cells. Infect. Immun. 55:1987;1774-1778.
14. Sato H., Okinaga K., Saito H. Role of pili in the pathogenesis of Pseudomonas aeruginosa burn infection. Microbiol. Immunol. 32:1988;131-139.
15. Sawada S., Suzuki M., Kawamura T., Fujinaga S., Masuho Y., Tomibe K. Protection against infection with Pseudomonas aeruginosa by passive transfer of monoclonal antibodies to lipopolysaccharides and outer membrane proteins. J. Infect. Dis. 150:1984;570-576.
16. Neely A.N., Holder I.A. A murine model with aspects of clinical relevance for the study of antibiotic-induced endotoxin release in septic hosts. J. Endotoxin Res. 3:1996;229-235.
17. Neely A.N., Orloff M.M., Holder I.A., Healy D.P. Effect of thermal injury on the adherence of Candida albicans to murine splenic tissue. Infect. Immun. 65:1997;3493-3495.
18. Bjorn M.J., Pavlovskis O.R., Thompson M.R., Iglewski B.H. Production of exoenzyme S during Pseudomonas aeruginosa infections of burned mice. Infect. Immun. 24:1979;387-442.
19. Neely A.N., Orloff M.M., Holder I.A. Disparities in efficacies of antiLPS agents in burned mouse models of LPS intoxication versus Gram-negative sepsis. J. Endotoxin Res. 3:1996;111-117.
20. Neely A.N., Orloff M.M., Imwalle A.R., Holder I.A. A murine model for studying endotoxemia and the efficacy of antiLPS agents in an immuno-compromised host. J. Endotoxin Res. 2:1995;115-120.
21. Stover G.B., Drake D.R., Montie T.C. Virulence of different Pseudomonas species in a burned mouse model: tissue colonization by Pseudomonas cepacia. Infect. Immun. 41:1983;1099-1104.
22. Carsiotis M., Stocker B.A.D., Holder I.A. Salmonella typhimurium virulence in a burned-mouse model. Infect. Immun. 57:1989;2842-2846.
23. Carsiotis M., Weinstein D.L., Karch H., Holder I.A., O'Brien A.D. Flagella of Salmonella typhimurium are a virulence factor in infected C57BL/6J mice. Infect. Immun. 46:1984;814-818.
24. Neely A.N., Childress C.M., Holder I.A. Effect of challenge with Candida albicans strains with different levels of virulence on plasma proteins in burned mice. Infect. Immun. 59:1991;1576-1578.
25. Neely A.N., Holder I.A. Postburn Candida infection and proteolytic activity: a model for sepsis in burn and surgical trauma. Wadstrom T., Holder I.A., Kronvall G., Molecular pathogenesis of surgical infections. 1994;257-271 Gustav Fischer Verlag, NY.
26. Neely A.N., Holder I.A. Effect of proteolytic activity on virulence of Candida albicans in burned mice. Infect. Immun. 58:1990;1527-1531.
27. Neely A.N., Holder I.A. Effects of immunoglobulin G and low-dose amphotericin B on Candida albicans infections in burned mice. Antimicrob. Agents Chemother. 36:1992;643-646.
28. Neely A.N., Law E.J., Holder I.A. Increased susceptibility to lethal Candida infections in burned mice preinfected with Pseudomonas aeruginosa of pretreated with proteolytic enzymes. Infect. Immun. 52:1986;200-204.
29. Neely A.N., Orloff M.M., Holder I.A. Candida albicans growth studies: a hypothesis for the pathogenesis of Candida infections in burns. J. Burn Care Rehab. 13:1992;323-329.
30. Fomsgaard A., Holder I.A. Effect of a human IgG preparation rich in antibodies to a wide range of lipopolysaccharides on Gram-negative bacterial sepsis in burned mice. APMIS. 101:1993;229-234.
31. Healy D.P., Clendening C.E., Neely A.N., Holder I.A. Antibiotic-induced endotoxin release is organism-dependent in experimental Gram-negative sepsis. J. Endotoxin Res. 4:1997;315-323.
32. Neely A.N., Miller R.G., Holder I.A. Proteolytic activity and fatal Gram-negative sepsis in burned mice: effect of exogenous proteinase inhibition. Infect. Immun. 62:1994;2158-2164.
33. Neely AN. A mouse model for studying Escherichia coli virulence factors in burn-immunocompromised hosts. ICAAC Abstr 1999 in press.
34. Nicas T.I., Iglewski B.H. The contribution of exoproducts to virulence of Pseudomonas aeruginosa. Can. J. Microbiol. 31:1985;387-392.
35. Pavlovskis O.R., Iglewski B.H., Pollack M. Mechanism of action of Pseudomonas aeruginosa exotoxin A in experimental mouse infections: adenosine diphosphate ribosylation of elongation factor 2. Infect. Immun. 19:1978;29-33.
36. Rumbaugh K.P., Griswold J.A., Hamood A.N. Contribution of the regulatory gene lasR to the pathogenesis of Pseudomonas aeruginosa infection of burned mice. J. Burn Care Rehab. 20:1999;42-49.
37. Saelinger C.B., Snell K., Holder I.A. Experimental studies on the pathogenesis of infections due to Pseudomonas aeruginosa: direct evidence for toxin production during Pseudomonas infection of burned skin tissues. J. Infect. Dis. 136:1977;555-561.
38. Snell K., Holder I.A., Leppla S.A., Saelinger C.B. Role of exotoxin and protease as possible virulence factors in experimental infections with Pseudomonas aeruginosa. Infect. Immun. 19:1978;839-845.
39. Vasil M.L., Berka R.M., Gray G.L., Pavlovskis O.R. Biochemical and genetic studies of iron-regulated (exotoxin A) and phosphate-regulated (hemolysin phopholipase C) virulence factors of Pseudomonas aeruginosa. Antibiot. Chemother. 36:1985;23-39.
40. Wretlind B., Bjorklind A., Pavlovskis O.R. Role of exotoxin A and elastase in the pathogenicity of Pseudomonas aeruginosa strain PAO experimental mouse burn infection. Microb. Path. 2:1987;397-404.
41. Holder IA, Neely AN, Yahr TL, Frank D. Genetic analysis of the type III effectors of P. aeruginosa in the burned mouse model. ASM Abstr 1999; B/D-336:95.
42. Iglewski B.H., Sadoff J., Bjorn M.J., Maxwell E.S. Pseudomonas aeruginosa exoenzyme S: an adenosine diphosphate rebosyltransferase distinct from toxin A. Proc. Natl. Acad. Sci. USA. 75:1978;3211-3215.
43. Nicas T.I., Bradley J., Lochner J.E., Iglewski B.H. The role of exoenzyme S in infections with Pseudomonas aeruginosa. J. Infect. Dis. 152:1985;716-721.
44. Nicas T.I., Iglewski B.H. Isolation and characterization of transposon-induced mutants of Pseudomonas aeruginosa deficient in production of exoenzyme S. Infect. Immun. 45:1984;470-474.
45. Holder I.A., Haidaris C.G. Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: extracellular protease and elastase as in vivo virulence factors. Can. J. Microbio. 25:1979;593-599.
46. Cicmanec J.F., Holder I.A. Growth of Pseudomonas aeruginosa in normal and burned skin extract: role of extracellular proteases. Infect. Immun. 25:1979;477-483.
47. Holder I.A., Neely A.N. Pseudomonas elastase acts as a virulence factor in burned hosts by Hageman factor-dependent activation of the host kinin cascade. Infect. Immun. 57:1989;3345-3348.
48. Holder I.A., Wheeler R. Experimental studies of the pathogenesis of infections owing to Pseudomonas aeruginosa: elastase and IgG protease. Can. J. Microbiol. 30:1984;1118-1124.
49. Pavlovskis O.R., Wretlind B. Assessment of protease (elastase) as a Pseudomonas aeruginosa virulence factor in experimental mouse burn infection. Infect. Immun. 24:1979;181-187.
50. Drake D., Montie T.C. Flagella, motility and invasive virulence of Pseudomonas aeruginosa. J. Gen. Microbiol. 134:1988;43-52.
51. Montie T.C., Doyle-Huntzinger D., Craven R.C., Holder I.A. Loss of virulence associated with absence of flagellum in an isogenic mutant of Pseudomonas aeruginosa in the burned-mouse model. Infect. Immun. 38:1982;1296-1298.
52. Meyer J.M., Neely A.N., Stintzi A., Georges C., Holder I.A. Pyoverdine is essential for virulence of Pseudomonas aeruginosa. Infect. Immun. 64:1996;518-523.
53. Sokol P.A. Surface expression of ferripyochelin-binding protein is required for virulence of Pseudomonas aeruginosa. Infect. Immun. 55:1987;2021-2025.
54. Goldberg J.B., Coyne M.J. Jr., Neely A.N., Holder I.A. Avirulence of a Pseudomonas aeruginosa alg C mutant in a burned-mouse model of infection. Infect. Immun. 63:1995;4166-4169.
55. Holder I.A., Neely A.N. Hageman factor-dependent kinin activation in burns and its theoretical relationship to postburn immunosuppression syndrome and infection. J. Burn Care Rehab. 11:1990;496-503.
56. Holder I.A., Neely A.N. The role of proteases in Pseudomonas infections in burns: a current hypothesis. Homma J.Y., Tanimoto H., Holder I.A., Hoiby N., Doring G., Pseudomonas aeruginosa in human diseases. 44:1991;99-105 Karger, Basel. [Antibiot. Chemother.].
57. Neely A.N., Hoover D.L., Holder I.A., Cross A.S. Circulating levels of tumour necrosis factor, interleukin 6 and proteolytic activity in a murine model of burn and infection. Burns. 22:1996;524-530.
58. Healy D.P., Verst-Brasch C.L., Clendening C.E., Neely A.N., Holder I.A. Kinetics of endotoxin and interleukin-6 following multiple doses of antibiotics for experimental Gram-negative bacterial sepsis. J. Endotoxin Res. 3:1996;93-101.
59. Healy D.P., Verst-Brasch C.L., Clendening C.E., Neely A.N., Holder I.A. Influence of drug class and dose size on antibiotic-induced endotoxin/IL-6 release and impact on efficacy of antiendotoxin antibody. J. Endotoxin Res. 3:1996;219-227.
60. Alexander J.W., Gianotti L., Pyles T., Carey M.A., Babcock G.F. Distribution and survival of Escherichia coli translocating from the intestine after thermal injury. Ann. Surg. 312:1991;558-567.
61. Eaves-Pyles T., Alexander J.W. Granulocyte colony-stimulating factor enhances killing of translocated bacteria but does not affect barrier function in a burn mouse model. J. Trauma. 41:1996;1013-1017.
62. Eaves-Pyles T., Alexander J.W. Rapid and prolonged impairment of gut barrier function after thermal injury in mice. Shock. 9:1998;95-100.
63. Gennari R., Alexander J.W., Pyles T., Hartmann S., Ogle C.K. Effects of antimurine interleukin-6 on bacterial translocation during gut-derived sepsis. Arch. Surg. 129:1994;1191-1197.
64. Gennari R., Alexander J.W., Eaves-Pyles T. Effect of different combinations of dietary additives on bacterial translocation and survival in gut-derived sepsis. JPEN. 19:1995;319-325.
65. Gennari R., Alexander J.W. Antiinterleukin-6 antibody treatment improves survival during gut-derived sepsis in a time-dependent manner by enhancing host defense. Crit. Care. Med. 23:1995;1945-1953.
66. Nelson J.L., Alexander J.W., Gianotti L., Chalk C.L., Pyles T. Influence of dietary fiber on microbial growth in vitro and bacterial translocation after burn injury in mice. Nutrition. 10:1994;32-36.
67. Peck M.D., Alexander J.W. Vitamin E supplementation does not improve survival from infection in mice when given after burn injury. J. Burn Care Rehab. 12:1991;41-42.
68. Holder I.A., Nathan P. Nonspecific therapy for protection of normal and burned mice from bacterial and fungal infections. Burns. 3:1976;14-19.
69. Holder I.A., Neely A.N. Combined host and specific antiPseudomonas-directed therapy for Pseudomonas aeruginosa infections in burned mice: experimental results and theoretical considerations. J. Burn Care Rehab. 10:1989;131-137.
70. Pavlovskis O.R., Pollack M., Callahan L.T. III, Iglewski B.H. Passive protection by antitoxin in experimental Pseudomonas aeruginosa burn infections. Infect. Immun. 18:1977;596-602.
71. Pavlovskis O.R., Edman D.C., Leppla S.H., Wretlind B., Lewis L.R., Martin K.E. Protection against experimental Pseudomonas aeruginosa infection in mice by active immunization with exotoxin A toxoids. Infect. Immun. 32:1981;681-689.
72. Holder I.A. Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: effect of treatment with protease inhibitors. Rev. Infect. Dis. 5:(5):1983;S914-S921.
73. Neely A.N., Holder I.A. Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: treatment using Pseudomonas hyperimmune globulin plus minocycline and effects of minocycline on protease elaboration. Serodiagn. Immunother. 1:1987;193-200.
74. Sokol P.A., Woods D.E. Characterization of antibody to the ferripyochelin-binding protein of Pseudomonas aeruginosa. Infect. Immun. 51:1986;896-900.
75. Baker N.R., Malik V., Galloway D.R., Deniz-Miz K.S., Kang P.J., Holder I., Neely A. Genetic immunization of mice with DNA encoding flagellin from Pseudomonas aeruginosa. ICAAC Abstr. G-87:1998;308.
76. Baker NR, Conwell J, Galloway DR, Kang PJ, Neely AN, Holder IA. Protection against lethal infection by pseudomonas aeruginosa in the burned mouse model following genetic immunization with DNA encoding type B flagellin. ASM Abstr 1999; B/D-287:85.
77. Holder I.A., Naglish J.G. Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: immunization using divalent flagella preparations. J. Trauma. 26:1986;118-122.
78. Hancock R.E.W., Mutharia L.M., Mouat C.A. Immunotherapeutic potential of monoclonal antibodies against Pseudomonas aeruginosa protein F. Eur. J. Clin. Microbiol. 4:1985;224-227.
79. Matthews-Greer J.M., Gilleland H.E. Jr. Outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine against heterologous immunotype strains in a burned mouse model. J. Infect. Dis. 155:1987;1282-1291.
80. Matthews-Greer J.M., Robertson D.E., Gilleland L.B., Gilleland H.E. Jr. Pseudomonas aeruginosa outer membrane protein F produced in Escherichia coli retains vaccine efficacy. Curr. Microbiol. 20:1990;171-175.
81. Terashima M., Uezumi I., Tomio T., et al. A protective human monoclonal antibody directed to the outer core region of Pseudomonas aeruginosa lipopolysaccharide. Infect. Immun. 59:1991;1-6.
82. Holder I.A., Orloff M., Neely A.N. Oral Pseudomonas aeruginosa immunization enhances survival in mice subsequently burned and infected with P. aeruginosa. Int. J. Antimicrob. Agents. 1:1992;245-252.
83. Pollack M., Pier G.B., Prescott R.K. Immunization with Pseudomonas aeruginosa high-molecular-weight polysaccharides prevents death from Pseudomonas burn infections in mice. Infect. Immun. 43:1984;759-760.
84. Schryvers A.B., Schollaardt T., Woods D.E., Williams K., Bryan L.E. Efficacy of oral immunization with Pseudomonas aeroginosa lipopolysaccharide. Serodiagn. Immunother. 1:1987;379-392.
85. Holder I.A., Naglish J.G. Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: treatment with intravenous immune globulin. Am. J. Med. 76:(3A):1984;161-167.
86. Holder I.A., Neely A.N. Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: passive intravenous immunotherapy using Pseudomonas globulin. Serodiagn. Immunother. 1:1987;153-162.
87. Holder I.A., Neely A.N. Pseudomonas hyperimmune globulin: antibiotic treatment of experimental Pseudomonas sepsis in burned mice. Antibiot. Chemother. 42:1989;109-123.
88. Neely A.N., Holder I.A. Use of passive immuotherapy in the treatment of experimental Pseudomonas aeruginosa infections in burns. Antibiot. Chemother. 39:1987;26-40.
89. Neely A.N., Holder I.A., Larrick J.W., Chong K.T. Comparison of pre- versus postsepsis treatment with polyclonal immunoglobulin versus O serotype specific monoclonal antibody in burned Pseudomonas aeruginosa infected mice. Serodiagn. Immunother. Infect. Dis. 4:1990;221-230.
90. Pollack M. Antibody activity against Pseudomonas aeruginosa in immune globulins prepared for intravenous use in humans. J. Infect. Dis. 147:1983;1090-1098.
91. Fang C.H., Peck M.D., Alexander J.W., Babcock G.R., Warden G.D. The effect of free radical scavengers on outcome after infection in burned mice. J. Trauma. 30:1990;453-456.
92. Holder I.A., Miller R.G., Neely A.N. Biologic response modifier OK-432 pretreatment reduces mortality in burned mice infected with Gram-negative bacteria. J. Burn Care Rehab. 14:1993;401-405.
93. Holder I.A., Miller R.G., Neely A.N. LC-9018 treatment enhances survival in Gram-negative burn wound sepsis. Int. J. Antimicrob. Agents. 2:1993;247-253.